Literature DB >> 23503843

Primary aldosteronism and impaired natriuresis in mice underexpressing TGFβ1.

Masao Kakoki1, Oleh M Pochynyuk, Catherine M Hathaway, Hirofumi Tomita, John R Hagaman, Hyung-Suk Kim, Oleg L Zaika, Mykola Mamenko, Yukako Kayashima, Kota Matsuki, Sylvia Hiller, Feng Li, Longquan Xu, Ruriko Grant, Alejandro M Bertorello, Oliver Smithies.   

Abstract

To uncover the potential cardiovascular effects of human polymorphisms influencing transforming growth factor β1 (TGFβ1) expression, we generated mice with Tgfb1 mRNA expression graded in five steps from 10% to 300% normal. Adrenal expression of the genes for mineralocorticoid-producing enzymes ranged from 50% normal in the hypermorphs at age 12 wk to 400% normal in the hypomorphs accompanied with proportionate changes in plasma aldosterone levels, whereas plasma volumes ranged from 50% to 150% normal accompanied by marked compensatory changes in plasma angiotensin II and renin levels. The aldosterone/renin ratio ranged from 0.3 times normal in the 300% hypermorphs to six times in the 10% hypomorphs, which have elevated blood pressure. Urinary output of water and electrolytes are markedly decreased in the 10% hypomorphs without significant change in the glomerular filtration rate. Renal activities for the Na(+), K(+)-ATPase, and epithelial sodium channel are markedly increased in the 10% hypomorphs. The hypertension in the 10% hypomorphs is corrected by spironolactone or amiloride at doses that do not change blood pressure in wild-type mice. Thus, changes in Tgfb1 expression cause marked progressive changes in multiple systems that regulate blood pressure and fluid homeostasis, with the major effects being mediated by changes in adrenocortical function.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23503843      PMCID: PMC3619322          DOI: 10.1073/pnas.1302641110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Altering the expression in mice of genes by modifying their 3' regions.

Authors:  Masao Kakoki; Yau-Sheng Tsai; Hyung-Suk Kim; Seigo Hatada; Dominic J Ciavatta; Nobuyuki Takahashi; Larry W Arnold; Nobuyo Maeda; Oliver Smithies
Journal:  Dev Cell       Date:  2004-04       Impact factor: 12.270

2.  TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II.

Authors:  Jo El J Schultz; Sandra A Witt; Betty J Glascock; Michelle L Nieman; Peter J Reiser; Stacey L Nix; Thomas R Kimball; Thomas Doetschman
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

3.  Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta.

Authors:  T A Mustoe; G F Pierce; A Thomason; P Gramates; M B Sporn; T F Deuel
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

4.  Transforming growth factor β1 +869T/C gene polymorphism and essential hypertension: a meta-analysis involving 2708 participants in the Chinese population.

Authors:  Li Yan-Yan
Journal:  Intern Med       Date:  2011-05-01       Impact factor: 1.271

5.  Regulation by adrenocorticotropin (ACTH), angiotensin II, transforming growth factor-beta, and insulin-like growth factor I of bovine adrenal cell steroidogenic capacity and expression of ACTH receptor, steroidogenic acute regulatory protein, cytochrome P450c17, and 3beta-hydroxysteroid dehydrogenase.

Authors:  C Le Roy; J Y Li; D M Stocco; D Langlois; J M Saez
Journal:  Endocrinology       Date:  2000-05       Impact factor: 4.736

Review 6.  Transforming growth factor-beta1 to the bone.

Authors:  Katrien Janssens; Peter ten Dijke; Sophie Janssens; Wim Van Hul
Journal:  Endocr Rev       Date:  2005-05-18       Impact factor: 19.871

7.  Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice.

Authors:  D E Clouthier; S A Comerford; R E Hammer
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

8.  Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1.

Authors:  N Inoue; R C Venema; H S Sayegh; Y Ohara; T J Murphy; D G Harrison
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-08       Impact factor: 8.311

9.  Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease.

Authors:  M M Shull; I Ormsby; A B Kier; S Pawlowski; R J Diebold; M Yin; R Allen; C Sidman; G Proetzel; D Calvin
Journal:  Nature       Date:  1992-10-22       Impact factor: 49.962

10.  TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function.

Authors:  Liang Zhou; Jared E Lopes; Mark M W Chong; Ivaylo I Ivanov; Roy Min; Gabriel D Victora; Yuelei Shen; Jianguang Du; Yuri P Rubtsov; Alexander Y Rudensky; Steven F Ziegler; Dan R Littman
Journal:  Nature       Date:  2008-03-26       Impact factor: 49.962

View more
  14 in total

1.  Deletion of diacylglycerol-responsive TRPC genes attenuates diabetic nephropathy by inhibiting activation of the TGFβ1 signaling pathway.

Authors:  Benju Liu; Xiju He; Shoutian Li; Benke Xu; Lutz Birnbaumer; Yanhong Liao
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  Low TGFβ1 expression prevents and high expression exacerbates diabetic nephropathy in mice.

Authors:  Catherine K Hathaway; Adil M H Gasim; Ruriko Grant; Albert S Chang; Hyung-Suk Kim; Victoria J Madden; C Robert Bagnell; J Charles Jennette; Oliver Smithies; Masao Kakoki
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-20       Impact factor: 11.205

3.  Protective effects of St. John's wort in the hepatic ischemia/reperfusion injury in rats.

Authors:  Süleyman Atalay; Belkıs Soylu; Aslı Aykaç; Ayliz Velioğlu Öğünç; Şule Çetinel; Naziye Özkan; Can Erzik; Ahmet Özer Şehirli
Journal:  Turk J Surg       Date:  2018-08-28

Review 4.  Transforming growth factor beta1 and aldosterone.

Authors:  Kota Matsuki; Catherine K Hathaway; Albert S Chang; Oliver Smithies; Masao Kakoki
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-03       Impact factor: 2.894

Review 5.  Review of Markers of Zona Glomerulosa and Aldosterone-Producing Adenoma Cells.

Authors:  Teresa M Seccia; Brasilina Caroccia; Elise P Gomez-Sanchez; Paul-Emmanuel Vanderriele; Celso E Gomez-Sanchez; Gian Paolo Rossi
Journal:  Hypertension       Date:  2017-09-25       Impact factor: 10.190

Review 6.  Transforming growth factor-β1 and diabetic nephropathy.

Authors:  Albert S Chang; Catherine K Hathaway; Oliver Smithies; Masao Kakoki
Journal:  Am J Physiol Renal Physiol       Date:  2015-12-30

7.  High Elmo1 expression aggravates and low Elmo1 expression prevents diabetic nephropathy.

Authors:  Catherine K Hathaway; Albert S Chang; Ruriko Grant; Hyung-Suk Kim; Victoria J Madden; C Robert Bagnell; J Charles Jennette; Oliver Smithies; Masao Kakoki
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

8.  GRAF3 serves as a blood volume-sensitive rheostat to control smooth muscle contractility and blood pressure.

Authors:  Xue Bai; Kevin Mangum; Masao Kakoki; Oliver Smithies; Christopher P Mack; Joan M Taylor
Journal:  Small GTPases       Date:  2018-01-07

9.  Mouse Models of Primary Aldosteronism: From Physiology to Pathophysiology.

Authors:  Leticia Aragao-Santiago; Celso E Gomez-Sanchez; Paolo Mulatero; Ariadni Spyroglou; Martin Reincke; Tracy Ann Williams
Journal:  Endocrinology       Date:  2017-12-01       Impact factor: 4.736

Review 10.  The role of transforming growth factor β1 in the regulation of blood pressure.

Authors:  Kota Matsuki; Catherine K Hathaway; Marlon G Lawrence; Oliver Smithies; Masao Kakoki
Journal:  Curr Hypertens Rev       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.